
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.
Fuqua says there is a fairly high frequency of this mutation in metastatic breast cancers. These mutations are estrogen independent, meaning that hormones are not needed to activate the receptor. The clinical assumption is that the mutation would confer resistance to an aromatase inhibitor, Fuqua says. However, there is no direct clinical evidence of this because the majority of patients that have been examined have undergone multiple rounds of hormonal therapy.




